These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7842530)

  • 1. Systemic cytokine measurements: their role in monitoring the response to therapy in patients with rheumatoid arthritis.
    Luqmani R; Sheeran T; Robinson M; Richardson K; Winkles J; Emery P
    Clin Exp Rheumatol; 1994; 12(5):503-8. PubMed ID: 7842530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary neopterin reflects clinical activity in patients with rheumatoid arthritis.
    Reibnegger G; Egg D; Fuchs D; Günther R; Hausen A; Werner ER; Wachter H
    Arthritis Rheum; 1986 Sep; 29(9):1063-70. PubMed ID: 3753537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of rheumatoid arthritis following adjunct statin therapy.
    Das S; Mohanty M; Padhan P
    Indian J Pharmacol; 2015; 47(6):605-9. PubMed ID: 26729950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of bed rest and intra-articular steroids on the acute phase response in rheumatoid arthritis.
    Sheeran TP; Roobottom CA; Wanklyn PD; Winkles J; Richardson K; Emery P
    Clin Exp Rheumatol; 1993; 11(1):49-52. PubMed ID: 8453797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs.
    Straub RH; Müller-Ladner U; Lichtinger T; Schölmerich J; Menninger H; Lang B
    Br J Rheumatol; 1997 Dec; 36(12):1298-303. PubMed ID: 9448591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and sRANKL Concentrations in Patients with Rheumatoid Arthritis.
    Kurz K; Herold M; Russe E; Klotz W; Weiss G; Fuchs D
    Dis Markers; 2015; 2015():276969. PubMed ID: 26576067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary neopterin excretion and dihydropteridine reductase activity in rheumatoid arthritis.
    Altindağ ZZ; Sahin G; Inanici F; Hasçelik Z
    Rheumatol Int; 1998; 18(3):107-11. PubMed ID: 9833251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.
    Bruns A; Nicaise-Roland P; Hayem G; Palazzo E; Dieudé P; Grootenboer-Mignot S; Chollet-Martin S; Meyer O
    Joint Bone Spine; 2009 May; 76(3):248-53. PubMed ID: 19208451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
    Ally MM; Hodkinson B; Meyer PW; Musenge E; Tintinger GR; Tikly M; Anderson R
    BMC Musculoskelet Disord; 2015 May; 16():130. PubMed ID: 26021985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study.
    Al-Gareeb AIA; Gorial FI; Mahmood AS
    Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies.
    Takeuchi T; Soen S; Ishiguro N; Yamanaka H; Tanaka S; Kobayashi M; Okubo N; Nitta T; Tanaka Y
    Mod Rheumatol; 2021 Jan; 31(1):34-41. PubMed ID: 31826682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.
    Aletaha D; Smolen JS
    Rheumatology (Oxford); 2002 Dec; 41(12):1367-74. PubMed ID: 12468815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumatoid arthritis phenotype associated with acute inflammation at the time of disease onset.
    Mullazehi M; Mathsson L; Lampa J; Rönnelid J
    Ann Rheum Dis; 2007 Apr; 66(4):537-41. PubMed ID: 17040962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: a one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study).
    Yazici Y; Curtis JR; Ince A; Baraf HS; Lepley DM; Devenport JN; Kavanaugh A
    Clin Exp Rheumatol; 2013; 31(3):358-64. PubMed ID: 23305631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics.
    Osiri M; Wongpiyabovorn J; Sattayasomboon Y; Thammacharoenrach N
    Clin Rheumatol; 2016 Jul; 35(7):1673-81. PubMed ID: 27188857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
    Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
    Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-articular steroids: confounder of clinical trials.
    Taylor HG; Fowler PD; David MJ; Dawes PT
    Clin Rheumatol; 1991 Mar; 10(1):38-42. PubMed ID: 2065506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis.
    Horneff G; Sack U; Kalden JR; Emmrich F; Burmester GR
    Clin Exp Immunol; 1993 Feb; 91(2):207-13. PubMed ID: 7679058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating cell free DNA: a marker to predict the therapeutic response for biological DMARDs in rheumatoid arthritis.
    Hashimoto T; Yoshida K; Hashimoto N; Nakai A; Kaneshiro K; Suzuki K; Kawasaki Y; Shibanuma N; Hashiramoto A
    Int J Rheum Dis; 2017 Jun; 20(6):722-730. PubMed ID: 27943573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.